Technical Analysis for IVA - Inventiva S.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 4.36 | 3.81% | 0.16 |
IVA closed up 3.81 percent on Monday, March 18, 2024, on 6.04 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 3.81% |
Alert | Time |
---|---|
Up 5% | about 15 hours ago |
Up 1 ATR | about 15 hours ago |
60 Minute Opening Range Breakdown | about 15 hours ago |
Upper Bollinger Band Resistance | about 15 hours ago |
5x Volume Pace | about 17 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/27/2024
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Alcohol Genetics Gene Expression Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease DNA Fibrosis Small Molecule Therapies Transcription Transcription Factors Epigenetics Transcription Factor Hepatitis A
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Alcohol Genetics Gene Expression Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease DNA Fibrosis Small Molecule Therapies Transcription Transcription Factors Epigenetics Transcription Factor Hepatitis A
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.04 |
52 Week Low | 2.22 |
Average Volume | 30,901 |
200-Day Moving Average | 3.97 |
50-Day Moving Average | 3.84 |
20-Day Moving Average | 3.73 |
10-Day Moving Average | 3.92 |
Average True Range | 0.24 |
RSI (14) | 66.44 |
ADX | 26.2 |
+DI | 34.05 |
-DI | 10.17 |
Chandelier Exit (Long, 3 ATRs) | 3.78 |
Chandelier Exit (Short, 3 ATRs) | 3.93 |
Upper Bollinger Bands | 4.31 |
Lower Bollinger Band | 3.14 |
Percent B (%b) | 1.04 |
BandWidth | 31.28 |
MACD Line | 0.11 |
MACD Signal Line | 0.02 |
MACD Histogram | 0.0828 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.86 | ||||
Resistance 3 (R3) | 4.85 | 4.67 | 4.77 | ||
Resistance 2 (R2) | 4.67 | 4.55 | 4.68 | 4.74 | |
Resistance 1 (R1) | 4.52 | 4.47 | 4.60 | 4.53 | 4.72 |
Pivot Point | 4.34 | 4.34 | 4.38 | 4.35 | 4.34 |
Support 1 (S1) | 4.19 | 4.22 | 4.27 | 4.20 | 4.00 |
Support 2 (S2) | 4.01 | 4.14 | 4.02 | 3.98 | |
Support 3 (S3) | 3.86 | 4.01 | 3.95 | ||
Support 4 (S4) | 3.87 |